Comparisons at baseline
| Ranibizumab | Bevacizumab | p Value | |
| Age (years) (SD) | 80.0 (7.30) | 77.0 (9.08) | 0.16* |
| Gender | |||
| Male | 18 | 9 | 0.99† |
| Female | 32 | 16 | 0.99† |
| Visual acuity (logMAR) (SD) | 0.644 (0.356) | 0.797 (0.346) | 0.15* |
| Central foveal point thickness (µm) (SD) | 278 (84) | 288 (94) | 0.66* |
| Total macular volume (mm3) (SD) | 7.22 (0.96) | 7.36 (1.08) | 0.59* |
| Mean (SD) no of OCTs per patient | 2.77 (0.88) | 2.76 (0.72) | 0.96* |
| Mean (SD) time until first OCT after treatment | 24.6 (13.6) | 26.8 (19.4) | 0.62* |
There was no difference in the baseline demographic characteristics of the ranibizumab versus bevacizumab-treated eyes.
*Two-sided Student t tests assuming unequal variance.
†Two-sided two-sample proportion Z test.
logMAR, log of minimal angle resolution; OCT, optical coherence tomography; SD, standard deviation.